Myeloproliferative Disease

Filter By:
08:54
As part of our coverage of the 2014 American Society of Hematology (ASH) annual meeting, Dr. Claire Harrison joined Patient Power to discuss the latest news on JAK inhibitors for the treatment of MPNs. Dr. Harrison talked about recent FDA approval of ruxolitinib (Jakafi®) for the treatment of polycy...
by:patientpower | 56 views
04:06
A molecular-based approach in MPN studies, which has improved understanding of driver mutations, has rapidly increased recent advances in clinical management. Combinational therapies are in preliminary stages and focus is on the Janus kinase (JAK) inhibitor, ruxolitinib, in combinations that enhance...
by:EMJ | 53 views
04:55
During the 2014 American Society of Hematology (ASH) annual meeting, Dr. Ruben Mesa from Mayo Clinic Arizona joined Patient Power to discuss the recent FDA approval of ruxolitinib (Jakafi®) for the treatment of polycythemia vera (PV)—the first medicine approved specifically to treat PV. Dr. Mesa exp...
by:patientpower | 61 views
31:00
As part of our coverage of the 2014 American Society of Hematology (ASH) annual meeting, Dr. Srdan Verstovsek from MD Anderson Cancer Center led a Patient Power roundtable discussion featuring Dr. Ross Levine from Memorial Sloan Kettering Cancer Center and Dr. Francesco Passamonti from Ospedale di C...
by:patientpower | 25 views
08:46
Anemia remains one of the greatest unmet needs in the treatment of myelofibrosis. At the 2014 American Society of Hematology Meeting, Dr. Ruben Mesa joined Patient Power to discuss MPN-related anemia and fatigue and what can be done about it. He explained the cause of anemia, why it varies for diffe...
by:patientpower | 49 views
05:04
During the 2014 American Society of Hematology (ASH) annual meeting, Dr. Bart Scott from Seattle Cancer Care Alliance joined Patient Power to share encouraging news for those living with myeloproliferat​ive neoplasms (MPNs). Dr. Scott gave an overview of all of the treatment news, including updates on JAK inhibitors in development, ruxolitinib for p...
by:patientpower | 104 views
20:10
In this “Best of the Day” presentation from the 2014 Annual Hematology Meeting in San Francisco, Dr. Joseph R. Mikhael and Dr. Srdan Verstovsek analyze and discuss pertinent clinical studies and late breaking updates pertaining to therapeutic strategies for the care of patients with myeloproliferat​ive neoplasms. This engaging conversation provides ...
by:imedex | 209 views
24:10
In this “Best of the Day” presentation from the 2014 Annual Hematology Meeting in San Francisco, Dr. Joseph R. Mikhael and Dr. David P. Steensma review and discuss pertinent clinical trials and late breaking updates on therapeutic options and management strategies for patients with myelodysplastic syndromes (MDS), acute lymphocytic leukemia (ALL) a...
by:imedex | 92 views
13:22
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr David Steensma (Dana-Farber Cancer Institute, Boston, MA), Dr Brent Wood (University of Washington, Seattle, WA), Prof Wendy Stock (University of Chicago Medical Center, Chicago, IL), Dr Christoph Röllig (Universitätskli​nikum Dresde...
by:EMJ | 151 views
06:32
Dr. Jason Gotlib, an MPN specialist from Stanford Cancer Institute, recently talked with Patient Power to talk about his current research focus and new agents that he is excited about for MPNs. Dr. Gotlib elaborated on drugs in development such as new JAK inhibitors and telomerase inhibitors and sha...
by:patientpower | 186 views
Please help us provide the best service.
I'm intersted in oncology videos because I'm a...

Oncologist 
Different type of MD 
Nurse 
Other oncology Professional 
Patient/Advocate 
Something Else 

No Thanks(close window)
Membership has its privileges.
 I want the OncologyTube newsletter 

 I want to share videos & receive the newsletter 

I already have an account log me in.


username:   password: remember me

Sign In

Username:
Password:
Remember me
Forgot your password?
Not Yet a Member? Sign up for FREE here!
(Skip Ad)